{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Nexalin Technology, Inc.
Is Nexalin Technology, Inc. overvalued or undervalued?
As of August 10, 2023, Nexalin Technology, Inc. is considered overvalued with troubling financial ratios, including a price-to-book value of 9.53 and a negative EV to EBITDA of -2.32, alongside a significant year-to-date stock decline of 61.96%.
Is Nexalin Technology, Inc. technically bullish or bearish?
As of May 5, 2025, Nexalin Technology, Inc. is in a bearish trend with moderate strength, indicated by bearish MACD, moving averages, and Bollinger Bands, along with underperformance compared to the S&P 500.
What does Nexalin Technology, Inc. do?
Nexalin Technology, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $0 million and a net loss of $2 million as of March 2025, with a market cap of $19.51 million. Key financial metrics indicate it is currently loss-making with a negative return on equity and no dividend yield.
How big is Nexalin Technology, Inc.?
As of Jun 18, Nexalin Technology, Inc. has a market capitalization of 19.51 million, with net sales of 0.14 million and a net profit of -8.55 million over the last four quarters. The company reported shareholder's funds of 3.68 million and total assets of 4.22 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
